Sanofi Consumer Healthcare India Limited ( ($IN:SANOFICONR) ) just unveiled an update. Sanofi Consumer Healthcare India ...

Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Sanofi Consumer Healthcare India has reported 1% rise in net profit to Rs 46.35 crore on a 6.8% increase in net sales to Rs 170.70 crore in Q3 FY25 as compared with Q3 FY24.

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

The company faced headwinds in the December 2024 quarter (Q4) as it reported a significant decline in earnings.

The company announced its Q4 results after-market hours. Its shares ended 0.4% higher on Thursday at ₹4,759.35 on the BSE.

Sanofi Consumer Healthcare India Q4 Results 2025 on 21 Feb, 2025: Revenue decreased by 20.53% YoY & profit decreased by 34.66% YoY, profit at ₹44.3 crore and revenue at ₹170.7 crore.

The Board of Directors of Sanofi Consumer Healthcare India Limited has recommended a final dividend of Rs. 55/- per equity share having face value of Rs.10/- each for the Financial Year ended 31st ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.